Table 2 Donor’s characteristics across Braak α-synuclein stages
Braak α-syn stage10 | Controls | Braak 1 | Braak 2 | Braak 3 | Braak 4 | Braak 5 | Braak 6 | p value |
|---|---|---|---|---|---|---|---|---|
N | 10 | 10 | 3 | 9 | 12 | 14 | 11 | |
Clinical PD N (% clinical PD) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (42%) | 12 (86%) | 10 (91%) | |
Age at death years; mean [range] | 76 [67, 85] | 85 [66, 95] | 81 [77, 86] | 87 [72, 95] | 84 [68, 96] | 78 [56, 88] | 75 [62, 86] | 0.003 |
Sex F/M (%F) | 4/6 (40%) | 5/5 (50%) | 3/0 (100%) | 5/4 (56%) | 6/6 (50%) | 4/10 (29%) | 4/7 (36%) | 0.4 |
PMD h:min mean [range] | 6:35 [3:50, 8:45] | 6:25 [4:25, 10:0] | 6:40 [4:35, 6:55] | 7:15 [4:50, 11:45] | 6:40 [4:20, 10:10] | 5:55 [4:10, 9:15] | 6:40 [3:30, 9:25] | 0.4 |
Thal phase70 N (%) | 0.11 | |||||||
A0 | 2 (20%) | 2 (20%) | 0 (0%) | 2 (22%) | 1 (8%) | 6 (43%) | 0 (0%) | |
A1 | 8 (80%) | 6 (60%) | 2 (67%) | 5 (56%) | 6 (50%) | 5 (36%) | 7 (64%) | |
A2 | 0 (0%) | 2 (20%) | 0 (0%) | 2 (22%) | 5 (42%) | 3 (21%) | 4 (36%) | |
A3 | 0 (0%) | 0 (0%) | 1 (33%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Braak NFT stage70 N (%) | 0.6 | |||||||
B0 | 2 (20%) | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) | |
B1 | 5 (50%) | 6 (60%) | 3 (100%) | 6 (67%) | 9 (75%) | 11 (79%) | 9 (82%) | |
B2 | 3 (30%) | 3 (30%) | 0 (0%) | 3 (33%) | 3 (25%) | 2 (14%) | 2 (18%) | |
B3 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
